Recently published data from a new study of Lundbeck and Teva’s Azilect could help boost sales of the Parkinson’s drug, says analyst Michael Friis Jørgensen from Alm. Brand Markets.
“It is difficult to offer an exact number, but on a whole it is of course positive. Whether it will give the same kind of boost that the Adagio studies did – I do not think so. It is an important product for Lundbeck, so it is positive for the company to get these data. Growth rates for the product have started declining following a very strong period,” he says and adds about the Adagio study: